Clinical trialNCT03621644Active, not recruitingInterventional

Stereotactic MRI-guided On-table Adaptive Radiation Therapy (SMART) for Locally Advanced Pancreatic Cancer

SponsorViewray Inc.Enrollment133Pancreatic Cancer

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

High-dose magnetic resonance imaging (MRI) guided hypofractionated radiation therapy delivered using daily adaptive dose planning has been shown in a retrospective study to result in improved overall survival, relative to patients receiving lower radiation doses, in patients with locally advanced pancreatic cancer, without increasing the rate of serious gastrointestinal toxicity. The goal of the proposed trial is to investigative in a controlled, prospective manner the robustness of this outcome, and to track quality of life over a 5-year trial period.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Daniel Low, PhD
University of California, Los Angeles
Principal Investigator
clinicaltrials.gov ↗
Michael Chuong, MD
Miami Cancer Institute
Principal Investigator
clinicaltrials.gov ↗
Parag J Parikh, MD
Henry Ford Health System
Principal Investigator
clinicaltrials.gov ↗
Percy Lee, MD
MD Anderson
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

13 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Israel

Assuta Medical Center
Tel Aviv, Israel

United States

Ucla
Los Angeles, California, United States
Miami Cancer Institute
Miami, Florida, United States
University of Miami
Miami, Florida, United States
Orlando Health
Orlando, Florida, United States
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Henry Ford Health Sciences
Detroit, Michigan, United States
Washington University
St Louis, Missouri, United States
Dartmouth-Hitchcock
Lebanon, New Hampshire, United States
Cornell University
New York, New York, United States
Providence Portland Cancer Center
Portland, Oregon, United States
Thomas Jefferson University
Philadelphia, Pennsylvania, United States
University of Wisconisin
Madison, Wisconsin, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 1 Jan 2019
Primary completion: 3 Aug 2022
Completion: 31 Jan 2027
Last update posted: 14 Oct 2022
Registered enrollment: 133
Registry id: NCT03621644

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.